Literature DB >> 25176645

Dominant lethal pathologies in male mice engineered to contain an X-linked DUX4 transgene.

Abhijit Dandapat1, Darko Bosnakovski1, Lynn M Hartweck1, Robert W Arpke1, Kristen A Baltgalvis2, Derek Vang3, June Baik4, Radbod Darabi4, Rita C R Perlingeiro4, F Kent Hamra5, Kalpna Gupta3, Dawn A Lowe2, Michael Kyba6.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is an enigmatic disease associated with epigenetic alterations in the subtelomeric heterochromatin of the D4Z4 macrosatellite repeat. Each repeat unit encodes DUX4, a gene that is normally silent in most tissues. Besides muscular loss, most patients suffer retinal vascular telangiectasias. To generate an animal model, we introduced a doxycycline-inducible transgene encoding DUX4 and 3' genomic DNA into a euchromatic region of the mouse X chromosome. Without induction, DUX4 RNA was expressed at low levels in many tissues and animals displayed a variety of unexpected dominant leaky phenotypes, including male-specific lethality. Remarkably, rare live-born males expressed DUX4 RNA in the retina and presented a retinal vascular telangiectasia. By using doxycycline to induce DUX4 expression in satellite cells, we observed impaired myogenesis in vitro and in vivo. This mouse model, which shows pathologies due to FSHD-related D4Z4 sequences, is likely to be useful for testing anti-DUX4 therapies in FSHD.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25176645      PMCID: PMC4188423          DOI: 10.1016/j.celrep.2014.07.056

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  58 in total

1.  Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.

Authors:  Sara T Winokur; Yi-Wen Chen; Peter S Masny; Jorge H Martin; Jeffrey T Ehmsen; Stephen J Tapscott; Silvere M van der Maarel; Yukiko Hayashi; Kevin M Flanigan
Journal:  Hum Mol Genet       Date:  2003-09-30       Impact factor: 6.150

2.  Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy.

Authors:  Petra G M van Overveld; Richard J F L Lemmers; Lodewijk A Sandkuijl; Leo Enthoven; Sara T Winokur; Floor Bakels; George W Padberg; Gert-Jan B van Ommen; Rune R Frants; Silvère M van der Maarel
Journal:  Nat Genet       Date:  2003-11-23       Impact factor: 38.330

3.  Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy.

Authors:  Richard J F L Lemmers; Mariëlle Wohlgemuth; Rune R Frants; George W Padberg; Eva Morava; Silvere M van der Maarel
Journal:  Am J Hum Genet       Date:  2004-10-04       Impact factor: 11.025

4.  Appropriate tissue- and cell-specific expression of a single copy human angiotensinogen transgene specifically targeted upstream of the HPRT locus by homologous recombination.

Authors:  B Cvetkovic; B Yang; R A Williamson; C D Sigmund
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

5.  Coats' disease and muscular dystrophy.

Authors:  R G Small
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1968 Mar-Apr

6.  On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy.

Authors:  G W Padberg; O F Brouwer; R J de Keizer; G Dijkman; C Wijmenga; J J Grote; R R Frants
Journal:  Muscle Nerve Suppl       Date:  1995

7.  Facioscapulohumeral dystrophy with cochlear hearing loss and tortuosity of retinal vessels.

Authors:  M A Gieron; J K Korthals; B G Kousseff
Journal:  Am J Med Genet       Date:  1985-09

8.  Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness.

Authors:  Siamak Agha-Mohammadi; Mark O'Malley; Abrak Etemad; Zhong Wang; Xiao Xiao; Michael T Lotze
Journal:  J Gene Med       Date:  2004-07       Impact factor: 4.565

9.  Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress.

Authors:  Sara T Winokur; Kathy Barrett; Jorge H Martin; James R Forrester; Mariella Simon; Rabi Tawil; Seung-Ah Chung; Peter S Masny; Denise A Figlewicz
Journal:  Neuromuscul Disord       Date:  2003-05       Impact factor: 4.296

10.  Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle.

Authors:  Davide Gabellini; Michael R Green; Rossella Tupler
Journal:  Cell       Date:  2002-08-09       Impact factor: 41.582

View more
  40 in total

1.  Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy.

Authors:  Kenji Rowel Q Lim; Rika Maruyama; Yusuke Echigoya; Quynh Nguyen; Aiping Zhang; Hunain Khawaja; Sreetama Sen Chandra; Takako Jones; Peter Jones; Yi-Wen Chen; Toshifumi Yokota
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

Review 2.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

Review 3.  Facioscapulohumeral Muscular Dystrophy.

Authors:  Jeffrey M Statland; Rabi Tawil
Journal:  Continuum (Minneap Minn)       Date:  2016-12

4.  Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells.

Authors:  Sujatha Jagannathan; Sean C Shadle; Rebecca Resnick; Lauren Snider; Rabi N Tawil; Silvère M van der Maarel; Robert K Bradley; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2016-10-15       Impact factor: 6.150

5.  Transcriptional Inhibitors Identified in a 160,000-Compound Small-Molecule DUX4 Viability Screen.

Authors:  Si Ho Choi; Darko Bosnakovski; Jessica M Strasser; Erik A Toso; Michael A Walters; Michael Kyba
Journal:  J Biomol Screen       Date:  2016-05-31

6.  Tissue-specific activities of the Fat1 cadherin cooperate to control neuromuscular morphogenesis.

Authors:  Françoise Helmbacher
Journal:  PLoS Biol       Date:  2018-05-16       Impact factor: 8.029

7.  AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD.

Authors:  Carlee R Giesige; Lindsay M Wallace; Kristin N Heller; Jocelyn O Eidahl; Nizar Y Saad; Allison M Fowler; Nettie K Pyne; Mustafa Al-Kharsan; Afrooz Rashnonejad; Gholamhossein Amini Chermahini; Jacqueline S Domire; Diana Mukweyi; Sara E Garwick-Coppens; Susan M Guckes; K John McLaughlin; Kathrin Meyer; Louise R Rodino-Klapac; Scott Q Harper
Journal:  JCI Insight       Date:  2018-11-15

8.  Mice expressing human ERAP1 variants associated with ankylosing spondylitis have altered T-cell repertoires and NK cell functions, as well as increased in utero and perinatal mortality.

Authors:  David P W Rastall; Fadel S Alyaquob; Patrick O'Connell; Yuliya Pepelyayeva; Douglas Peters; Sarah Godbehere-Roosa; Cristiane Pereira-Hicks; Yasser A Aldhamen; Andrea Amalfitano
Journal:  Int Immunol       Date:  2017-06-01       Impact factor: 4.823

9.  Smchd1 haploinsufficiency exacerbates the phenotype of a transgenic FSHD1 mouse model.

Authors:  Jessica C de Greef; Yvonne D Krom; Bianca den Hamer; Lauren Snider; Yosuke Hiramuki; Rob F P van den Akker; Kelsey Breslin; Miha Pakusch; Daniela C F Salvatori; Bram Slütter; Rabi Tawil; Marnie E Blewitt; Stephen J Tapscott; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

10.  Crystal Structure of the Double Homeodomain of DUX4 in Complex with DNA.

Authors:  John K Lee; Darko Bosnakovski; Erik A Toso; Tracy Dinh; Surajit Banerjee; Thomas E Bohl; Ke Shi; Kayo Orellana; Michael Kyba; Hideki Aihara
Journal:  Cell Rep       Date:  2018-12-11       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.